Partial
Mostly Aligned
Patient Risk:
Low
Summary
Most pharmacology/label-structure statements about cobicistat and TYBOST align with the provided label excerpts (e.g., CYP3A inhibition; indications; coadministration requirement; renal monitoring concepts; contraindication framework). However, multiple claims about patent checking/Orange Book and generic entry timing are not supported or addressed by the provided prescribing information, making the response only partially aligned to the label content.
Category Scores
Accurate Statements
Tybost is the brand name for cobicistat.
Label is for TYBOST (cobicistat); Sections 12.1/12.3 describe cobicistat as the active ingredient/mechanism.
Cobicistat is a medicine used to boost the effect of certain HIV medicines by inhibiting the CYP3A enzyme.
Section 12.1 Mechanism of Action: CYP3A inhibitor increases systemic exposure of atazanavir/darunavir.
Patent questions about "Tybost" typically refer to patents covering cobicistat itself and/or cobicistat's use in combination regimens for HIV treatment.
No support in provided prescribing information excerpts (label-only evaluation).
Patent timelines depend on the specific patent numbers, whether they are composition-of-matter vs. method-of-use patents, and any extensions or regulatory exclusivities tied to the product.
No support in provided prescribing information excerpts (label-only evaluation).
Without the exact Tybost patent numbers and expiry dates, generic launch dates for generic cobicistat cannot be confirmed.
No support in provided prescribing information excerpts (label-only evaluation).
Patent expiry generally determines when competitors can file for and/or launch generic versions of small-molecule drugs like cobicistat.
No support in provided prescribing information excerpts (label-only evaluation).
People search Tybost patents to determine whether a competitor can market a generic cobicistat before patent expiry.
No support in provided prescribing information excerpts (label-only evaluation).
People search Tybost patents to determine what patents are listed as covering the reference product.
No support in provided prescribing information excerpts (label-only evaluation).
People search Tybost patents to determine whether litigation or settlements affect the timing of generic entry.
No support in provided prescribing information excerpts (label-only evaluation).
Patent listings and market-exclusivity information for prescription drugs are commonly tracked through the U.S. FDA's drug product patent and exclusivity systems (for example, via the FDA's Orange Book).
No support in provided prescribing information excerpts (label-only evaluation).
FDA's drug product patent and exclusivity systems tie patents to the listed drug and specific expiration dates.
No support in provided prescribing information excerpts (label-only evaluation).
Unsupported Statements
Patent questions about "Tybost" typically refer to patents covering cobicistat itself and/or cobicistat's use in combination regimens for HIV treatment.
Provided TYBOST prescribing information excerpts do not discuss patents or generic entry.
Patent timelines depend on the specific patent numbers, whether they are composition-of-matter vs. method-of-use patents, and any extensions or regulatory exclusivities tied to the product.
Not addressed in provided prescribing information excerpts.
Without the exact Tybost patent numbers and expiry dates, generic launch dates for generic cobicistat cannot be confirmed.
Not addressed in provided prescribing information excerpts.
Patent expiry generally determines when competitors can file for and/or launch generic versions of small-molecule drugs like cobicistat.
Not addressed in provided prescribing information excerpts.
People search Tybost patents to determine whether a competitor can market a generic cobicistat before patent expiry.
Not addressed in provided prescribing information excerpts.
People search Tybost patents to determine what patents are listed as covering the reference product.
Not addressed in provided prescribing information excerpts.
People search Tybost patents to determine whether litigation or settlements affect the timing of generic entry.
Not addressed in provided prescribing information excerpts.
Patent listings and market-exclusivity information for prescription drugs are commonly tracked through the U.S. FDA's drug product patent and exclusivity systems (for example, via the FDA's Orange Book).
Not addressed in provided prescribing information excerpts.
FDA's drug product patent and exclusivity systems tie patents to the listed drug and specific expiration dates.
Not addressed in provided prescribing information excerpts.
Contradictions
Important Omissions
No on-label claims about TYBOST indications, dosing, contraindications, warnings/precautions, drug interactions, adverse reactions, or monitoring were actually stated by the AI response (beyond general CYP3A inhibition/patent context).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-relevant safety/clinical mechanism content presented (CYP3A inhibition) does not provide unsafe dosing or contraindication misuse. Most other statements are about patents/generic timing and do not directly instruct patient use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several statements are outside the scope of the prescribing information (patent/Orange Book/generic entry timing) and are unsupported by the provided label excerpts.
Suggested Improvement
Limit the response to prescribing-information-supported items (e.g., TYBOST indications, coadministration/dosing requirements, contraindicated drugs/interactions, and renal monitoring statements), and omit or clearly separate non-label patent/exclusivity discussion.